Effect of oral VCE-004.8, a cannabidiol quinol derivative, on experimental autoimmune encephalomyelitis

Abstract

Multiple Sclerosis (MS) is characterized by a combination of inflammatory and neurodegenerative processes that are dominantin different stages of the disease. Thus, immunosuppression is the goldstandard for the inflammatory stage and novel remyelination therapies are being pursued to restore lost function. While angiogenesis andblood-brain barrier(BBB)disruption are potentially negative in inflammatory phases, angiogenesis mediated by the stabilization of HIF-1αcould be beneficial for neuroprotection and axonal regeneration in remitting phases and progressive forms of the disease. Therefore, the development of complementary treatments aimed at axonal repair and remyelination and/or slowing the progression of the disease through neuroprotectionand axonal regeneration remain the most important objective in the clinical management of chronic progressive MS.